Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively. Investment will expand product
Understanding the mechanism of toxicity: OOC’s crucial role
It’s commonly acknowledged that the current drug discovery process is inefficient with large numbers of drugs failing in the clinic. Almost a third
CN Bio selected for NC3R’s SensOoChip Challenge to develop advanced Heart-on-a-Chip
Part of the wider CRACK IT scheme – the multi-challenge competition aims to leverage CN Bio's existing OOC expertise - our MPS development and
CN Bio appoints Joseph Parisi as US Director of Sales
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market CN Bio, a leading Organ-on-a-Chip (OOC)
CN Bio and Altis Biosystems partnership
CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies CN Bio and
PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment
CN Bio PhysioMimix® Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing. CN Bio, a
OBN Awards 2023 winner!
CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA Six-year collaboration
CN Bio appoints Neil Rumbelow as Director of Product Development
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems CN Bio, a
CN Bio showcased in PwC UK’s ‘Life Sciences Future 50’ report 2023
We are delighted to announce that we are showcased as one of the 50 companies in PwC UK’s 'Life Sciences Future 50' report. The report illustrates